Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731716 | 0.89 | SLC9A1 (0.68) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL14796568 | 0.89 | SLC9A1 (0.79) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL29482278 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL1834794 | 0.82 | SLC9A1 (1.00) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL318888 | 0.82 | SLC9A1 (1.00) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL7011474 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL7667065 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL7667067 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL5332501 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL730354 | 0.81 | SLC9A1 (0.66) | SLC9A1NPC1RAB9AMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212328-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORP (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8071764-B2 | Compounds of reverse turn mimetics and the use thereof (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-23 | — | — | US | disclosed |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-09-09 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| CN-1088709-C | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 2002-08-07 | — | — | CN | disclosed |
| CN-1284075-A | Novel compounds having CGMP-PDE inhibitory effect | MOCHIDA PHARM CO LTD (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| CN-1052984-C | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 2000-05-31 | — | — | CN | disclosed |
| US-6066672-A | OF GIVEN FORMULA COMPRISING A SUBSTITUTED AMINOALKYL(AMIDO OR ALKYLAMINO)ALKYL(AMIDO OR ALKYLAMINO)ALKYL(ALKENE, ALKYL OR ALKOXYCARBONYL) | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| CN-1229082-A | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 1999-09-22 | — | — | CN | disclosed |
| EP-0882699-A1 | AMINO COMPOUNDS AND ANGIOTENSIN IV RECEPTOR AGONISTS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | SLC9A1 4608/4885NPC1 4428/4885RAB9A 3203/4885 |
| US-20100228027-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (2) | MCL1, BID, MYADM | SLC9A1 4576/4885NPC1 4464/4885RAB9A 2796/4885 |
| US-20100240662-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, WNT3, APC | SLC9A1 4224/4885NPC1 3162/4885RAB9A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.